AbbVie's newest HA filler indication targets the décolletage and neck, a high-volume treatment area with limited approved options.
Allergan Aesthetics received FDA approval for SKINVIVE by JUVÉDERM for improvement of neck appearance, expanding the product's labeled indications beyond its original cheek approval. SKINVIVE is a smooth, low-viscosity HA filler designed for superficial placement and gradual collagen stimulation—a positioning distinct from traditional volumizing fillers like JUVÉDERM Ultra or Voluma.
The neck approval is commercially significant: practitioners already inject this area off-label with various HA products, but labeled indication allows for direct marketing, formulary inclusion, and rebate-program eligibility. The décolletage and neck represent a high-volume, recurring-treatment zone—patients often return annually or bi-annually for maintenance, creating predictable revenue.
SKINVIVE approval for neck appearance expands a high-volume, recurring-treatment indication.
This move also signals Allergan's strategy to differentiate SKINVIVE as a dedicated skin-quality and subtle-lift product, competing implicitly against Galderma's Restylane Vital and other superficial-placement fillers. For practices, the approval simplifies compliance documentation and insurance coding.
Source: original report ↗
Frequently asked questions
What is SKINVIVE by JUVÉDERM used for now that it has FDA approval for the neck?
SKINVIVE is now FDA-approved for improvement of neck and décolletage appearance in addition to its original cheek indication. It's a smooth, low-viscosity HA filler designed for superficial placement and gradual collagen stimulation, making it distinct from traditional volumizing fillers like JUVÉDERM Ultra or Voluma.
Why is the neck indication expansion commercially important for med spas and practices?
The neck and décolletage are high-volume, recurring-treatment zones where patients typically return annually or bi-annually for maintenance, creating predictable revenue. Labeled indication also allows direct marketing, formulary inclusion, and rebate-program eligibility—advantages over off-label use.
How does SKINVIVE differ from other JUVÉDERM fillers like Ultra and Voluma?
SKINVIVE is a low-viscosity HA filler designed for superficial placement and gradual collagen stimulation, positioning it as a skin-quality and subtle-lift product rather than a volumizer. Traditional JUVÉDERM products like Ultra and Voluma are designed for deeper placement and more substantial volume restoration.
What competitor products does SKINVIVE compete against for neck and superficial treatments?
SKINVIVE competes against Galderma's Restylane Vital and other superficial-placement fillers in the skin-quality segment. The FDA approval strengthens SKINVIVE's market position by providing a labeled indication in a treatment area where competitors already have established presence.
Does SKINVIVE's neck approval simplify insurance coding and compliance for practices?
Yes—the labeled indication simplifies compliance documentation and insurance coding compared to off-label use. Practitioners previously injected the neck area off-label with various HA products, but the FDA approval streamlines the administrative and regulatory process.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
